For more information and whether or not you qualify for a study, please email our research coordinator: Rebecca Sweeny
Observation and Translation of Axial Spondyloarthritis:
Current Target Population: Seropositive Rheumatoid Arthritis
– Inclusion: Clinical Diagnosis of RA with +RF and/or CCP
– Exclusion: prior negative testing for HLA-B27
– Remuneration: $25 for saliva to test for HLA-B27 and if positive $50 for a blood draw
– Contact: Megan Arb; meganarb@wustl.edu
ACR/EULAR Classification Criteria for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis
Current Target Population: Cancer patients who have received ICI therapy and developed inflammatory arthritis
-Inclusion Criteria: Adults with new musculoskeletal symptoms after exposure to at least one dose of immunotherapy (CTLA4, PD1 and/or PDL1 inhibitor) for cancer
-Exclusion Criteria: Pre-existing inflammatory arthritis or systemic autoimmune rheumatic disease
-Contact: Rebecca Sweeney; r.a.sweeney@wustl.edu
Lupus Nexus/Landmark
Current Target Population: Adults with Systemic Lupus Erythematosus
-Inclusion Criteria: Adults with SLE that fulfill EULAR/ACR criteria
-Exclusion Criteria: Unable to meet protocol visit requirements
-Remuneration: $45 per visit, +$40 for stool sample received
-Contact: Maribel Chebuske; chebuske.m@wustl.edu
Kypha -Complement activation signatures in complement-mediated diseases:
Evaluating the impact of pre-analytical handling on complement biomarker levels using the Research Use Only (RUO), and not intended for use in diagnosic procedures,ii Kypha instruments (Kypha Comp act® and RapiPlexTM) on single and multiplex Rapid Test kits with single and multiplex Controls, such as Level 1, Level 2, and Level 3) in patients with complement-mediated diseases. The aim is to understand the impact of sample storage time and temperature on complement activation measurements in complement-mediated diseases. This information will inform best practices for sample handling in these diseases, ultimately allowing for accurate and interpretable complement measurements to inform patient care.
– Current Target Population: Persons with complement-mediated diseases 18 years and older.
– Inclusion Criteria: Diagnosed by a physician with a complement-mediated disease (such as thrombotic microangiopathy, lupus, etc).
– Exclusion Criteria: Minors (<18 years old), Pregnant/lactating women, Chronic viral illnesses (i.e. hepatitis B, C, or HIV), End-stage kidney or liver disease, Non-English speakers requiring a translator.
– Remunaration: $25 prepaid gift card.
– Email: chebuske.m@wustl.edu